Oseltamivir phosphate

The chemical name of oseltamivir phosphate is (3R, 4R, 5S)-4-acetamide-5-amino-3-(1-propoxyethyl)-1-cyclohexane-1-carboxylic acid ethyl ester phosphate. The molecular formula is C16H28N2O4H3PO4, and the molecular weight is 410.4

Interaction with influenza vaccine: There is no evaluation of the interaction between oseltamivir phosphate and live attenuated influenza vaccine. However, due to the possible interaction between the two, oseltamivir phosphate should not be taken within two weeks of taking live attenuated influenza vaccine, and live attenuated influenza vaccine should not be used within 48 hours after taking oseltamivir phosphate unless clinically necessary. Because oseltamivir phosphate, as an antiviral drug, may inhibit the replication of live vaccine viruses. Trivalent inactivated influenza vaccine can be used at any time before or after taking oseltamivir phosphate. Pharmacological and pharmacokinetic study data show that there is basically no significant clinically significant interaction between oseltamivir phosphate and other drugs. Oseltamivir phosphate is rapidly converted into active metabolites (oseltamivir carboxylate) by esterases mainly distributed in the liver. There are few reports of drug interactions related to competing esterases in the literature. The low protein binding rate of oseltamivir and its active metabolites suggests that drug interactions related to protein binding are unlikely to occur. In vitro studies have shown that neither oseltamivir phosphate nor its active metabolites are good substrates for P450 mixed function oxidase or glucuronyl transferase (see [Pharmacokinetics]). There is no mechanism of drug interaction with oral contraceptives. Cimetidine is a nonspecific inhibitor of cytochrome P450 isoenzymes and can compete with alkaline or cationic substances for renal tubular secretion, but it has no effect on the plasma concentration of oseltamivir or its active metabolites. Therefore, clinical drug interactions related to changes in gastric pH (antacids) and competitive clearance with the renal tubular secretion pathway are unlikely to occur. However, there are no in vivo studies on the interaction between oseltamivir phosphate and antacids. Drug interactions related to competitive secretion with renal tubules are unlikely to have important clinical significance, because most drugs have a wide safety range, and the excretion of active metabolites of oseltamivir phosphate has two pathways: glomerular filtration and renal tubular secretion, and the clearance capacity of these two pathways is very large. However, it should be used with caution in combination with drugs that are also secreted by the kidneys and have a narrow safety range (such as chlorsulfuronamide, methotrexate, and phenylbutazone). When used in combination with probenecid, the body utilization of active metabolites is increased by 2 times due to the decreased ability of the renal tubular secretion. However, due to the wide safety margin of active metabolites, no dose adjustment is required when co-administered with probenecid. Co-administration with amoxicillin does not change the plasma concentrations of the two drugs, indicating that the competitive effect of anion pathway elimination is not significant. In post-marketing surveillance, there have been case reports of interactions with ganciclovir, which is also secreted through the renal tubules. Co-administration with paracetamol (acetaminophen) did not change the plasma concentrations of oseltamivir, its active metabolites, or paracetamol. No changes in the pharmacokinetic parameters of oseltamivir, its active metabolite (oseltamivir carboxylate), or aspirin were found when oseltamivir (75 mg, twice daily for 4 days) was taken with aspirin (single dose of 900 mg). No changes in the pharmacokinetic parameters of oseltamivir and its active metabolite (oseltamivir carboxylate) were found when oseltamivir (single dose of 150 mg) was taken with a single dose of an antacid containing aluminum hydroxide and magnesium hydroxide or a single dose of an antacid containing calcium carbonate. In the Phase III clinical study of influenza treatment and influenza prevention, oseltamivir phosphate has been used in combination with some commonly used drugs, such as ACE inhibitors (enalapril, captopril), thiazide diuretics (bendroflumethiazide), antibiotics (penicillin, cephalosporin, azithromycin, erythromycin, doxycycline), H2 receptor blockers (ranitidine, cimetidine), beta-receptor blockers (propranolol), xanthines (theophylline), sympathomimetic drugs (pseudoephedrine), opioids (codeine), steroid hormones, inhaled bronchodilators and analgesics (aspirin, ibuprofen and paracetamol). No adverse events were observed or their incidence was changed when oseltamivir phosphate was used in combination with these drugs.

Oseltamivir phosphate

Interaction with influenza vaccine: There is no evaluation of the interaction between oseltamivir phosphate and live attenuated influenza vaccine. However, due to the possible interaction between the two, oseltamivir phosphate should not be taken within two weeks of taking live attenuated influenza vaccine, and live attenuated influenza vaccine should not be used within 48 hours after taking oseltamivir phosphate unless clinically necessary. Because oseltamivir phosphate, as an antiviral drug, may inhibit the replication of live vaccine viruses. Trivalent inactivated influenza vaccine can be used at any time before or after taking oseltamivir phosphate. Pharmacological and pharmacokinetic study data show that there is basically no significant clinically significant interaction between oseltamivir phosphate and other drugs. Oseltamivir phosphate is rapidly converted into active metabolites (oseltamivir carboxylate) by esterases mainly distributed in the liver. There are few reports of drug interactions related to competing esterases in the literature. The low protein binding rate of oseltamivir and its active metabolites suggests that drug interactions related to protein binding are unlikely to occur. In vitro studies have shown that neither oseltamivir phosphate nor its active metabolites are good substrates for P450 mixed function oxidase or glucuronyl transferase (see [Pharmacokinetics]). There is no mechanism of drug interaction with oral contraceptives. Cimetidine is a nonspecific inhibitor of cytochrome P450 isoenzymes and can compete with alkaline or cationic substances for renal tubular secretion, but it has no effect on the plasma concentration of oseltamivir or its active metabolites. Therefore, clinical drug interactions related to changes in gastric pH (antacids) and competitive clearance with the renal tubular secretion pathway are unlikely to occur. However, there are no in vivo studies on the interaction between oseltamivir phosphate and antacids. Drug interactions related to competitive secretion with renal tubules are unlikely to have important clinical significance, because most drugs have a wide safety range, and the excretion of active metabolites of oseltamivir phosphate has two pathways: glomerular filtration and renal tubular secretion, and the clearance capacity of these two pathways is very large. However, it should be used with caution in combination with drugs that are also secreted by the kidneys and have a narrow safety range (such as chlorsulfuronamide, methotrexate, and phenylbutazone). When used in combination with probenecid, the body utilization of active metabolites is increased by 2 times due to the decreased ability of the renal tubular secretion. However, due to the wide safety margin of active metabolites, no dose adjustment is required when co-administered with probenecid. Co-administration with amoxicillin does not change the plasma concentrations of the two drugs, indicating that the competitive effect of anion pathway elimination is not significant. In post-marketing surveillance, there have been case reports of interactions with ganciclovir, which is also secreted through the renal tubules. Co-administration with paracetamol (acetaminophen) did not change the plasma concentrations of oseltamivir, its active metabolites, or paracetamol. No changes in the pharmacokinetic parameters of oseltamivir, its active metabolite (oseltamivir carboxylate), or aspirin were found when oseltamivir (75 mg, twice daily for 4 days) was taken with aspirin (single dose of 900 mg). No changes in the pharmacokinetic parameters of oseltamivir and its active metabolite (oseltamivir carboxylate) were found when oseltamivir (single dose of 150 mg) was taken with a single dose of an antacid containing aluminum hydroxide and magnesium hydroxide or a single dose of an antacid containing calcium carbonate. In the Phase III clinical study of influenza treatment and influenza prevention, oseltamivir phosphate was used in combination with some commonly used drugs, such as ACE inhibitors (enalapril, captopril), thiazide diuretics (bendroflumethiazide), antibiotics (penicillin, cephalosporin, azithromycin, erythromycin, doxycycline), H2 receptor blockers (ranitidine, cimetidine), beta-blockers (propranolol), xanthines (theophylline), sympathomimetic drugs (pseudoephedrine), opioids (codeine), steroid hormones, inhaled bronchodilators and analgesics (aspirin, ibuprofen and paracetamol). No adverse events were observed or their incidence was changed when oseltamivir phosphate was used in combination with these drugs.

The main ingredient of this product is oseltamivir phosphate, and its chemical name is: (3R,4R,5S)-4-acetylamino-5-amino-3 (1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester phosphate. Molecular weight: C16H28N2O4.H3PO4

Interaction with influenza vaccine: There is no evaluation of the interaction between oseltamivir phosphate and live attenuated influenza vaccine. However, due to the possible interaction between the two, oseltamivir phosphate should not be taken within two weeks of taking live attenuated influenza vaccine, and live attenuated influenza vaccine should not be used within 48 hours after taking oseltamivir phosphate unless clinically necessary. Because oseltamivir phosphate, as an antiviral drug, may inhibit the replication of live vaccine viruses. Trivalent inactivated influenza vaccine can be used at any time before or after taking oseltamivir phosphate. Pharmacological and pharmacokinetic study data show that there is basically no significant clinically significant interaction between oseltamivir phosphate and other drugs. Oseltamivir phosphate is rapidly converted into active metabolites (oseltamivir carboxylate) by esterases mainly distributed in the liver. There are few reports of drug interactions related to competing esterases in the literature. The low protein binding rate of oseltamivir and its active metabolites suggests that drug interactions related to protein binding are unlikely to occur. In vitro studies have shown that neither oseltamivir phosphate nor its active metabolites are good substrates for P450 mixed function oxidase or glucuronyl transferase (see [Pharmacokinetics]). There is no mechanism of drug interaction with oral contraceptives. Cimetidine is a nonspecific inhibitor of cytochrome P450 isoenzymes and can compete with alkaline or cationic substances for renal tubular secretion, but it has no effect on the plasma concentration of oseltamivir or its active metabolites. Therefore, clinical drug interactions related to changes in gastric pH (antacids) and competitive clearance with the renal tubular secretion pathway are unlikely to occur. However, there are no in vivo studies on the interaction between oseltamivir phosphate and antacids. Drug interactions related to competitive secretion with renal tubules are unlikely to have important clinical significance, because most drugs have a wide safety range, and the excretion of active metabolites of oseltamivir phosphate has two pathways: glomerular filtration and renal tubular secretion, and the clearance capacity of these two pathways is very large. However, it should be used with caution in combination with drugs that are also secreted by the kidneys and have a narrow safety range (such as chlorsulfuronamide, methotrexate, and phenylbutazone). When used in combination with probenecid, the body utilization of active metabolites is increased by 2 times due to the decreased ability of the renal tubular secretion. However, due to the wide safety margin of active metabolites, no dose adjustment is required when co-administered with probenecid. Co-administration with amoxicillin does not change the plasma concentrations of the two drugs, indicating that the competitive effect of anion pathway elimination is not significant. In post-marketing surveillance, there have been case reports of interactions with ganciclovir, which is also secreted through the renal tubules. Co-administration with paracetamol (acetaminophen) did not change the plasma concentrations of oseltamivir, its active metabolites, or paracetamol. No changes in the pharmacokinetic parameters of oseltamivir, its active metabolite (oseltamivir carboxylate), or aspirin were found when oseltamivir (75 mg, twice daily for 4 days) was taken with aspirin (single dose of 900 mg). No changes in the pharmacokinetic parameters of oseltamivir and its active metabolite (oseltamivir carboxylate) were found when oseltamivir (single dose of 150 mg) was taken with a single dose of an antacid containing aluminum hydroxide and magnesium hydroxide or a single dose of an antacid containing calcium carbonate. In the Phase III clinical study of influenza treatment and influenza prevention, oseltamivir phosphate has been used in combination with some commonly used drugs, such as ACE inhibitors (enalapril, captopril), thiazide diuretics (bendroflumethiazide), antibiotics (penicillin, cephalosporin, azithromycin, erythromycin, doxycycline), H2 receptor blockers (ranitidine, cimetidine), beta-receptor blockers (propranolol), xanthines (theophylline), sympathomimetic drugs (pseudoephedrine), opioids (codeine), steroid hormones, inhaled bronchodilators and analgesics (aspirin, ibuprofen and paracetamol). No adverse events were observed or their incidence was changed when oseltamivir phosphate was used in combination with these drugs.